Results 21 to 30 of about 8,864 (209)

Long-term clinical outcomes of [177Lu]Lu-DOTATATE in patients with metastatic neuroendocrine tumors [PDF]

Frontiers in Oncology
The incidence of gastroenteropancreatic neuroendocrine tumors has been rising and these tumors are usually only diagnosed at a metastatic stage.
Sabah Iqbal, Eric Zhuang, Moses Raj, Nathan Bahary, Dulabh K. Monga   +4 more
doaj   +2 more sources

Global insights into [177Lu]Lu-DOTATATE safety: a comprehensive disproportionality analysis from the WHO pharmacovigilance database

Scientific Reports
Peptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE is an effective treatment for metastatic or inoperable neuroendocrine tumors. While clinical trials have demonstrated its efficacy and safety in a limited number of selected patients, real ...
Typhanie Ladrière, Basile Chrétien, Anne-Laure Bignon, Karine Bouhier-Leporrier, Charles Dolladille, Jonathan Vigne   +5 more
doaj   +2 more sources

The South Australian 177Lu-DOTATATE peptide receptor radionuclide therapy service: an 11-year review of toxicity, health-related quality of life, and survival [PDF]

ESMO Gastrointestinal Oncology
Background: The aim of this study was to audit clinical and patient-reported outcomes of patients treated with [177Lu]-DOTA-octreotate (177Lu-DOTATATE) at a single Australian centre over an 11-year period.
L.M. Altus, J.C. Forster, J. Mercurio, M. Kitchener, N. Corsini, M. Nenke, T. Price, D. Patel, R. Chew, D. Moffat, S. Unger, G. Cehic   +11 more
doaj   +2 more sources

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors [PDF]

, 2017
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options.
Weber, M, Freemantle, N, Courbon, F, Kvols, L, Wolin, E, DELLE FAVE, Gianfranco, Giammarile, F, Baum, Rp, Srirajaskanthan, R, Santoro, P, Manoharan, P, Anthony, L, Berlin, J, Thevenet, T, Yao, J., Taieb, D, Lebtahi, R, Garbus, S, Ruszniewski, P, Hobday, T, Brianzoni, E, Azevedo, I, Schipper, M, Chiara Grana, M, Mittra, E, Van Cutsem, E, Severi, S, Bodei, L, Grossman, A, Hendifar, A, Reed, N, Kulkarni, Hr, Erion, Jl, Scheidhauer, K, Yao, J, Öberg, K, El Haddad, G, Morse, M, Baudin, E, Benson, A, Kulke, M, Delpassand, E, Kunz, Pl, Al‐nahhas, A, Benson, Ab, Lopera Sierra, M, Kwekkeboom, D, Bushnell, D, Mora, J, Pavel, M, Grande, E, Jacene, H, Mariani, G, Caplin, M, Krenning, E, Rindi, G, Metz, D, Ansquer, C, Chasen, B, Sundin, A, Seregni, E, O'Dorisio, Tm, Strosberg, J, Kulke, Mh   +63 more
core   +3 more sources

Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE [PDF]

, 2021
We report the impact of 177Lu-DOTATATE treatment on abdominal pain, diarrhea, and flushing, symptoms that patients with advanced midgut neuroendocrine tumors often find burdensome.
Baum, Richard P., Hendifar, Andrew E.,, Chasen, Beth R., Krenning, Eric P.,, Wolin, Edward M.,, El-Haddad, Ghassan, Krenning, Eric P, Strosberg, Jonathan R., Strosberg, Jonathan R.,, Chasen, Beth R.,, Caplin, Martyn E.,, Ruszniewski, Philippe, Santoro, Paola,, Caplin, Martyn E, Baum, Richard P, Chasen, Beth A., Strosberg, Jonathan R, Baum, Richard P.,, Öberg, Kjell,, Leeuwenkamp, Oscar R, Chasen, Beth A, El-Haddad, Ghassan,, Krenning, Eric P., Öberg, Kjell, Ruszniewski, Philippe,, Leeuwenkamp, Oscar R., Caplin, Martyn E., Kulke, Matthew H, Hendifar, Andrew E, Kulke, Matthew H.,, Wolin, Edward M., Hendifar, Andrew E., Bushnell, David L, Bushnell, David L.,, Kulke, Matthew H., Leeuwenkamp, Oscar R.,, Broberg, Per,, Srirajaskanthan, Rajaventhan, Broberg, Per, Wolin, Edward M, Santoro, Paola, Srirajaskanthan, Rajaventhan,, Bushnell, David L.   +42 more
core   +2 more sources

Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation

Case Reports in Oncology, 2023
Based on the results of the NETTER-1 trial, peptide receptor radionuclide therapy with Lutetium-177 (177Lu) – DOTATATE is authorized for the treatment of neuroendocrine tumors (NET) grade 1 (G1) and grade 2 (G2) of the intestine.
Anke Kröcher, Gunnar Folprecht, Robert Winzer, Mildred Sergon, Martin Bornhäuser, Jörg Kotzerke, Claudia Brogsitter   +6 more
doaj   +1 more source

p53-Mediated Radiosensitization of 177Lu-DOTATATE in Neuroblastoma Tumor Spheroids

, 2021
p53 is involved in DNA damage response and is an exciting target for radiosensitization in cancer. Targeted radionuclide therapy against somatostatin receptors with 177Lu-DOTATATE is currently being explored as a treatment for neuroblastoma.
Nestor, M, Hanna Berglund, Berglund, Hanna,, Jha, Preeti,, Hariri, M, Nelander, Sven, Krona, Cecilia,, Sara Lundsten, Lundsten, Sara,, Lundsten, Sara, Jha, P, Krona, Cecilia, Krona, C, Sven Nelander, Marika Nestor, Berglund, H, Hariri, Mehran,, Nelander, Sven,, Nestor, Marika, Berglund, Hanna, David P. Lane, Lane, DP, Mehran Hariri, Lundsten, S, Nestor, Marika,, Lane, David P.,, Cecilia Krona, Lane, David P., Preeti Jha, Jha, Preeti, Nelander, S, Hariri, Mehran   +31 more
core   +1 more source

Targeted radionuclide therapy for patients with neuroendocrine tumours with focus on normal tissue response in 177-Lu-DOTATATE treatment [PDF]

, 2016
Targeted radionuclide therapy with 177Lu-DOTATATE for patients with neuroendocrine tumours utilises the frequent overexpressing of somatostatin receptors on the tumour cells.
Svensson, Johanna
core   +1 more source

Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough

EJNMMI Research, 2022
Background Receptor saturation during peptide receptor radionuclide therapy (PRRT) could result in altered [177Lu]Lu-HA-DOTATATE uptake in tumors and organs.
Hinke Siebinga, Chayenne H. A. M. Veerman, Linda de Wit-van der Veen, Marcel P. M. Stokkel, Jeroen J. M. A. Hendrikx, Else A. Aalbersberg   +5 more
doaj   +1 more source

Research Progress of 177Lu-DOTATATE in the Treatment of Neuroendocrine Tumor Patients with Environmental Radiation Safety

Journal of Isotopes, 2022
Neuroendocrine tumors (NENs) are rare tumors arising from neuroendocrine cells distributed throughout the body. 177Lu-DOTATATE has been shown to significantly prolong the progression-free survival of patients, and has been widely used abroad.
MA Guangyu;BA Jiantao;PENG Cheng;CHEN Yingmao
doaj